No Data
sh pharma (02607.HK) received a shareholding of 0.4 million H shares by SIIC International Investment Company Limited and its affiliates, worth approximately 5.1357 million Hong Kong dollars.
On November 12, it was reported that according to the documents disclosed by the Hong Kong Stock Exchange on November 12, SIIC International Investment Company Limited increased its shareholding in sh pharma (02607.HK) by 400,000 H-shares at an average price of HKD 12.8393 per share on November 7, amounting to approximately HKD 5.1357 million. After the increase, SIIC International Investment Company Limited's latest shareholding is 0.23 billion shares.
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Everbright Securities: Empowering commercial health insurance to promote payment diversification, medical insurance prepayment alleviates funding pressure.
After the implementation of the medical insurance prepayment system, it is expected to effectively alleviate the financial pressure of medical institutions in the corresponding areas, thereby improving the enterprise account payment status of pharmaceutical procurement and consumables channels, conducive to the overall development of the cash flow chain of medical institutions-pharmaceutical distribution-pharmaceutical manufacturing.
Citi: Maintains a "buy" rating on sh pharma with a target price lowered to 15.3 Hong Kong dollars.
Citigroup released a research report stating to maintain a 'buy' rating on sh pharma (02607), lowering the earnings forecast per share for each year from 2024 to 2026 by 6%, 5%, and 5% respectively, reflecting challenges faced by the pharmaceutical sector and the narrowing profit margin of the distribution business. The target price for the listed in hong kong shares was lowered from 16.2 Hong Kong dollars to 15.3 Hong Kong dollars. The report mentioned that the company's third-quarter revenue increased by 8% year-on-year to 70 billion RMB (below), affected by a decrease in gross margin, with net profit dropping by 6% year-on-year to 1.1 billion RMB. The gross margin for the period dropped to 10%, compared to 10.6% in the same period of the previous fiscal year. The company's management expects to launch one innovative drug next year.
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Multiple bullish factors boost pharmaceutical stocks listed in Hong Kong, institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
No Data
No Data